SCHEMBL6521116

SCHEMBL6521116

CC(C)(C)CC(=O)Nc1cc(NC(=O)NC2CCCCC2)cc(Cl)c1O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.52
NPC1 O15118 8/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
EPHX2 P34913 4/20 0.52
TSHR P16473 3/20 0.52
HTT P42858 1/20 0.52
EPHX1 P07099 6/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
GAA P10253 1/20 0.43
CXCR2 P25025 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349050 0.84 RAB9A (0.54) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL4347487 0.84 EPHX1 (0.56) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL4347065 0.81 RAB9A (0.66) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL6568610 0.79 RAB9A (0.63) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL4352945 0.75 RAB9A (0.59) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL4347284 0.75 RAB9A (0.58) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL4354309 0.75 RAB9A (0.66) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL6567606 0.74 L3MBTL1 (0.53) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL4357508 0.74 RAB9A (0.57) RAB9ANPC1SMN1; SMN2EPHX2TSHR
SCHEMBL6521514 0.74 ALDH1A1 (0.54) RAB9ANPC1SMN1; SMN2EPHX2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 RAB9A 4228/4885NPC1 815/4885SMN1; SMN2 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.